Silencing of Girdin suppresses the malignant behavior of colorectal carcinoma cells

Lu,Jia; Zhang,Lin; Zhou,Hongyan; Du,Zhenwu; Zhang,Guizhen

doi:10.3892/or.2018.6511

Silencing of Girdin suppresses the malignant behavior of colorectal carcinoma cells

Authors:
- Jia Lu
- Lin Zhang
- Hongyan Zhou
- Zhenwu Du
- Guizhen Zhang
View Affiliations

Affiliations: Central Laboratory, The Second Hospital of Jilin University, Changchun, Jilin 130041, P.R. China, Central Laboratory, The Second Hospital of Jilin University, Changchun, Jilin 130041, P.R. China, Department of Ophthalmology, China‑Japan Union Hospital of Jilin University, Changchun, Jilin 130033, P.R. China
Published online on: June 20, 2018 https://doi.org/10.3892/or.2018.6511
Pages: 887-894

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

The aim of the present study was to investigate the effect of the actin‑binding protein Girdin on the proliferation, invasion and migration of colorectal cancer (CRC) cells. Cultured CRC cells (LoVo cell line) were transfected by Girdin‑specific and control shRNA constructs and analyzed for proliferation, invasion and migration by the MTT, Transwell and wound‑healing assays, respectively. The activation of the Janus kinase/signal transducer and activator of transcription (JAK/STAT) signaling pathway and expression of proinflammatory cytokines was examined by western blotting and ELISA assay, respectively. The effect of Girdin silencing on CRC growth was also evaluated in a xenograft model using nude mice, which were subcutaneously injected with Girdin‑deficient and negative control LoVo cells and analyzed for tumor volume and weight. Transfection of LoVo cells with Girdin‑specific shRNA inhibited Girdin mRNA expression to 27.5% and protein expression to 36.7% when compared with expression levels in the control cells (P<0.001) and significantly demonstrated suppression of LoVo cell proliferation (P<0.05), invasion (P<0.01) and migration (P<0.01). Furthermore, Girdin silencing downregulated the phosphorylation of the signaling proteins JAK (by 42%, P<0.001) and STAT3 (by 34%, P<0.01) and the content of IFN (by 28%, P<0.001) and IL‑6 (by 44%, P<0.001) compared to the control. Notably, inhibition of Girdin expression effectively suppressed tumorigenicity of LoVo cells in vivo as evidenced by the reduced volume (P<0.05) and weight (P<0.05) of the tumors derived from Girdin shRNA‑transfected LoVo cells compared to those from the control cells. In conclusion, the silencing of Girdin expression inhibited the malignant behavior of CRC cells via the downregulation of the JAK/STAT signaling pathway, indicating Girdin as a potential therapeutic target in CRC. In the present study, we revealed, for the first time, that the malignant behavior of CRC cells depended on the expression of an actin‑binding protein, Girdin. Silencing of Girdin expression by specific shRNA suppressed the proliferation, invasion, and migration of CRC cells through the decrease in proinflammatory cytokines IFN and IL‑6 and the downregulation of the JAK/STAT signaling pathway. Our findings indicated that Girdin expression may be a potential novel therapeutic target in CRC.

View Figures

View References

1	Ahmad R, Alam M, Hasegawa M, Uchida Y, Al-Obaid O, Kharbanda S and Kufe D: Targeting MUC1-C inhibits the AKT-S6K1-elF4A pathway regulating TIGAR translation in colorectal cancer. Mol Cancer. 16:332017. View Article : Google Scholar : PubMed/NCBI
2	Wang C, Yue Y, Shao B, Qiu Z, Mu J, Tang J, Han X, Xiang T and Ren G: Dickkopf-related protein 2 is epigenetically inactivated and suppresses colorectal cancer growth and tumor metastasis by antagonizing Wnt/β-catenin signaling. Cell Physiol Biochem. 41:1709–1724. 2017. View Article : Google Scholar : PubMed/NCBI
3	Chen W, Zheng R, Baade PD, Zhang S, Zeng H, Bray F, Jemal A, Yu XQ and He J: Cancer statistics in china, 2015. CA Cancer J Clin. 66:115–132. 2016. View Article : Google Scholar : PubMed/NCBI
4	Siegel RL, Miller KD and Jemal A: Cancer statistics, 2016. CA Cancer J Clin. 66:7–30. 2016. View Article : Google Scholar : PubMed/NCBI
5	Peeters M, Price T and Van Laethem JL: Anti-epidermal growth factor receptor monotherapy in the treatment of metastatic colorectal cancer: Where are we today? Oncologist. 14:29–39. 2009. View Article : Google Scholar : PubMed/NCBI
6	Li J, Zhang N, Zhang R, Sun L, Yu W, Guo W, Gao Y, Li M, Liu W, Liang P, et al: CDC5L promotes htert expression and colorectal tumor growth. Cell Physiol Biochem. 41:2475–2488. 2017. View Article : Google Scholar : PubMed/NCBI
7	Kelly C and Cassidy J: Chemotherapy in metastatic colorectal cancer. Surg Oncol. 16:65–70. 2007. View Article : Google Scholar : PubMed/NCBI
8	Qi J, Yu Y, Akilli Ozturk O, Holland JD, Besser D, Fritzmann J, Wulf-Goldenberg A, Eckert K, Fichtner I and Birchmeier W: New Wnt/β-catenin target genes promote experimental metastasis and migration of colorectal cancer cells through different signals. Gut. 65:1690–1701. 2016. View Article : Google Scholar : PubMed/NCBI
9	Hagan S, Orr MC and Doyle B: Targeted therapies in colorectal cancer-an integrative view by PPPM. EPMA J. 4:32013. View Article : Google Scholar : PubMed/NCBI
10	Ou B, Zhao J, Guan S, Feng H, Wangpu X, Zhu C, Zong Y, Ma J, Sun J, Shen X, et al: CCR4 promotes metastasis via ERK/NF-κB/MMP13 pathway and acts downstream of TNF-α in colorectal cancer. Oncotarget. 7:47637–47649. 2016. View Article : Google Scholar : PubMed/NCBI
11	Valastyan S and Weinberg RA: Tumor metastasis: Molecular insights and evolving paradigms. Cell. 147:275–292. 2011. View Article : Google Scholar : PubMed/NCBI
12	Alberts SR, Horvath WL, Sternfeld WC, Goldberg RM, Mahoney MR, Dakhil SR, Levitt R, Rowland K, Nair S, Sargent DJ, et al: Oxaliplatin, fluorouracil, and leucovorin for patients with unresectable liver-only metastases from colorectal cancer: A north central cancer treatment group phase ii study. J Clin Oncol. 23:9243–9249. 2005. View Article : Google Scholar : PubMed/NCBI
13	Jove R: Preface: STAT signaling. Oncogene. 19:2466–2467. 2000. View Article : Google Scholar : PubMed/NCBI
14	Uchiyama T, Takahashi H, Endo H, Sugiyama M, Sakai E, Hosono K, Nagashima Y, Inayama Y, Wada K, Hippo Y, et al: Role of the long form leptin receptor and of the STAT3 signaling pathway in colorectal cancer progression. Int J Oncol. 39:935–940. 2011.PubMed/NCBI
15	Kim HS, Kim T, Ko H, Lee J, Kim YS and Suh YG: Identification of galiellalactone-based novel STAT3-selective inhibitors with cytotoxic activities against triple-negative breast cancer cell lines. Bioorg Med Chem. 25:5032–5040. 2017. View Article : Google Scholar : PubMed/NCBI
16	Jiang C, Long J, Liu B, Xu M, Wang W, Xie X, Wang X and Kuang M: miR-500a-3p promotes cancer stem cells properties via STAT3 pathway in human hepatocellular carcinoma. J Exp Clin Cancer Res. 36:992017. View Article : Google Scholar : PubMed/NCBI
17	Niwa Y, Kanda H, Shikauchi Y, Saiura A, Matsubara K, Kitagawa T, Yamamoto J, Kubo T and Yoshikawa H: Methylation silencing of SOCS-3 promotes cell growth and migration by enhancing JAK/STAT and FAK signalings in human hepatocellular carcinoma. Oncogene. 24:6406–6417. 2005. View Article : Google Scholar : PubMed/NCBI
18	Aggarwal BB, Kunnumakkara AB, Harikumar KB, Gupta SR, Tharakan ST, Koca C, Dey S and Sung B: Signal transducer and activator of transcription-3, inflammation, and cancer: How intimate is the relationship? Ann N Y Acad Sci. 1171:59–76. 2009. View Article : Google Scholar : PubMed/NCBI
19	Wang SW and Sun YM: The IL-6/JAK/STAT3 pathway: Potential therapeutic strategies in treating colorectal cancer (Review). Int J Oncol. 44:1032–1040. 2014. View Article : Google Scholar : PubMed/NCBI
20	Wang SW, Hu J, Guo QH, Zhao Y, Cheng JJ, Zhang DS, Fei Q, Li J and Sun YM: AZD1480, a JAK inhibitor, inhibits cell growth and survival of colorectal cancer via modulating the JAK2/STAT3 signaling pathway. Oncol Rep. 32:1991–1998. 2014. View Article : Google Scholar : PubMed/NCBI
21	Jiang P, Enomoto A, Jijiwa M, Kato T, Hasegawa T, Ishida M, Sato T, Asai N, Murakumo Y and Takahashi M: An actin-binding protein Girdin regulates the motility of breast cancer cells. Cancer Res. 68:1310–1318. 2008. View Article : Google Scholar : PubMed/NCBI
22	Gu F, Wang L, He J, Liu X, Zhang H, Li W, Fu L and Ma Y: Girdin, an actin-binding protein, is critical for migration, adhesion, and invasion of human glioblastoma cells. J Neurochem. 131:457–469. 2014. View Article : Google Scholar : PubMed/NCBI
23	Wang H, Misaki T, Taupin V, Eguchi A, Ghosh P and Farquhar MG: GIV/girdin links vascular endothelial growth factor signaling to Akt survival signaling in podocytes independent of nephrin. J Am Soc Nephrol. 26:314–327. 2015. View Article : Google Scholar : PubMed/NCBI
24	Dunkel Y, Ong A, Notani D, Mittal Y, Lam M, Mi X and Ghosh P: STAT3 protein up-regulates Gα-interacting vesicle-associated protein (GIV)/Girdin expression, and GIV enhances STAT3 activation in a positive feedback loop during wound healing and tumor invasion/metastasis. J Biol Chem. 287:41667–41683. 2012. View Article : Google Scholar : PubMed/NCBI
25	Jin F, Liu C, Guo Y, Chen H and Wu Y: Clinical implications of Girdin and PI3K protein expression in breast cancer. Oncol Lett. 5:1549–1553. 2013. View Article : Google Scholar : PubMed/NCBI
26	Zhao L, Ma S, Liu Q and Liang P: Clinical implications of girdin protein expression in glioma. ScientificWorldJournal. 2013:9860732013. View Article : Google Scholar : PubMed/NCBI
27	Wang Y, Yuan L, Yang XM, Wei D, Wang B, Sun XX, Feng F, Nan G, Wang Y, Chen ZN and Bian H: A chimeric antibody targeting CD147 inhibits hepatocellular carcinoma cell motility via FAK-PI3K-Akt-Girdin signaling pathway. Clin Exp Metastasis. 32:39–53. 2015. View Article : Google Scholar : PubMed/NCBI
28	Wang C, Lin J, Li L and Wang Y: Expression and clinical significance of girdin in gastric cancer. Mol Clin Oncol. 2:425–428. 2014. View Article : Google Scholar : PubMed/NCBI
29	Zhang YJ, Li AJ, Han Y, Yin L and Lin MB: Inhibition of Girdin enhances chemosensitivity of colorectal cancer cells to oxaliplatin. World J Gastroenterol. 20:8229–8236. 2014. View Article : Google Scholar : PubMed/NCBI
30	Ni W, Fang Y, Tong L, Tong Z, Yi F, Qiu J, Wang R and Tong X: Girdin regulates the migration and invasion of glioma cells via the PI3K-Akt signaling pathway. Mol Med Rep. 12:5086–5092. 2015. View Article : Google Scholar : PubMed/NCBI
31	Yu L, Sun Y, Li J, Wang Y, Zhu Y, Shi Y, Fan X, Zhou J, Bao Y, Xiao J, et al: Silencing the Girdin gene enhances radio-sensitivity of hepatocellular carcinoma via suppression of glycolytic metabolism. J Exp Clin Cancer Res. 36:1102017. View Article : Google Scholar : PubMed/NCBI
32	Schonberg DL, Lubelski D, Miller TE and Rich JN: Brain tumor stem cells: Molecular characteristics and their impact on therapy. Mol Aspects Med. 39:82–101. 2014. View Article : Google Scholar : PubMed/NCBI
33	Chang KC, Wu MH, Jones D, Chen FF and Tseng YL: Activation of STAT3 in thymic epithelial tumours correlates with tumour type and clinical behaviour. J Pathol. 210:224–233. 2006. View Article : Google Scholar : PubMed/NCBI
34	Murray PJ: The JAK-STAT signaling pathway: Input and output integration. J Immunol. 178:2623–2629. 2007. View Article : Google Scholar : PubMed/NCBI
35	Kowshik J, Baba AB, Giri H, Deepak Reddy G, Dixit M and Nagini S: Astaxanthin inhibits JAK/STAT-3 signaling to abrogate cell proliferation, invasion and angiogenesis in a hamster model of oral cancer. PLoS One. 9:e1091142014. View Article : Google Scholar : PubMed/NCBI
36	Peng HX, Wu WQ, Yang DM, Jing R, Li J, Zhou FL, Jin YF, Wang SY and Chu YM: Role of B7-H4 siRNA in Proliferation, Migration, and Invasion of LOVO colorectal carcinoma cell line. Biomed Res Int. 2015:3269812015. View Article : Google Scholar : PubMed/NCBI